TBIO - Translate Bio

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Codex DNA GAAP EPS of -$0.28 beats by $0.13, revenue of $9.47M beats by $2.27M
• Telesis Bio expects more than 190% Y/Y increase in Q4 revenue
• Telesis Bio GAAP EPS of -$0.42 beats by $0.05, revenue of $6.68M beats by $1.38M; raises FY22 revenue outlook
• Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
• RIGL, REV and BOXD among pre market gainers
• Codex DNA slide continues as shares down ~70% over last month
• Codex DNA top and bottom lines misses lead to 24% decline
• Codex DNA GAAP EPS of -$0.43 misses by $0.06, revenue of $3.08M misses by $0.75M
• Despite 22% gain today, Codex DNA still well down from June IPO price
• Pfizer CEO: Strategic mRNA investments will leverage 'powerful technology' to create new products
• Pfizer in pact with Codex DNA to develop mRNA-based vaccines and biotherapies
• Pfizer deal gives key validation to Codex DNA's technology - KeyBanc
• Codex DNA partners with Pfizer to advance the DNA platform
• Codex DNA acquires Eton Bioscience for ~$13M
• Codex DNA EPS misses by $0.05, misses on revenue
• Meet members of the 2021 IPO class: life sciences tools (part 2)
• Codex DNA EPS misses by $0.69, beats on revenue
• Codex DNA up 7% on Maravai supply deal for mRNA capping technology
• Street sees green on psychedelic drug developers, and more in today's analyst action
• Codex raises additional $16M as IPO underwriters exercise option